Back to top

Analyst Blog

Shire plc (SHPG - Analyst Report) recently received positive news when the U.S. Food & Drug Administration (FDA) approved a third manufacturing facility at Mass. U.S. for the production of active pharmaceutical ingredient (API) in type I Gaucher disease drug, Vpriv.

The news should relieve Shire as it had received a complete response letter (CRL) for the production of Vpriv's API at the Lexington, Mass. manufacturing facility.

We note that Shire intends to add a manufacturing capacity in the Lexington facility to support the rapid growth of Vpriv and Replagal. The facility was initially approved for the purification of Replagal API.

Subsequently, Shire submitted regulatory filings with both the European Medicines Agency (EMA) and the FDA for the production of Vpriv API at the new facility in Nov 2011. The EMA’s Committee for Medicinal Products for Human Use approved the production of Vpriv in this facility in Feb 2012, which was later adopted by the European Commission in Mar 2012. Shire has submitted its response to the matters raised by the FDA in Oct 2012.

Vpriv generated sales of $342.7 million in 2013. Hence, we are encouraged by the recent approval which should ensure a smooth supply of  Vpriv .

Last week, Shire reported strong fourth quarter results. Shire is well placed in the attention deficit and hyperactivity disorder (ADHD) market driven by key drug Vyvanse and is working on a label expansion of the drug.

ViroPharma's lead drug Cinryze is approved in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adults with hereditary hereditary angioedema (HAE). Cinryze complements Shire's Firazyr which is indicated for the on-demand treatment of acute HAE attacks. 

We are positive on Shire’s acquisition of ViroPharma which will strengthen its HAE franchise as Cinryze and Firazyr are two complementary therapies for the treatment of HAE. Meanwhile, Shire’s efforts to realign its business structure to drive growth and innovation are noteworthy.

Shire currently carries a Zacks Rank #2 (Buy). Other pharma stocks that look attractive at current levels include Endocyte Inc. (ECYT - Snapshot Report), Forest Laboratories and Auxilium Pharmaceuticals Ltd. (AUXL - Analyst Report). All the three stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 114.56 +6.04%
LANNETT COM… LCI 40.60 +3.26%
US SILICA H… SLCA 69.46 +2.15%
ERBA DIAGNO… ERB 3.87 +1.84%
GENTIVA HEA… GTIV 18.01 +1.35%